Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 94

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 94
---
 to pathogen exposure. Multiple preclinical studies have shown that systemic pretreatment with PHAD results in a significantly augmented immune response leading to significantly reduced duration and severity of infection following bacterial challenge with either gram -positiveor gram -negativebacteria. Gemini-PBI The Gemini -PBIprogram is being developed, through a license agreement with Vanderbilt University, as a potential therapy for the prevention of infection in severe burn patients requiring hospitalization. We believe Gemini administration to severe burn patients will augment the patients immune response to resist infection by activating the body’s immune system to better and more rapidly respond to pathogen exposure. Preclinical studies in a burn model have shown that systemic administration of MPLA (a bacterially derived mixture of PHAD -likemolecules) post -burnresults in a significantly augmented immune response leading to significantly reduced duration and severity of infection following pseudomonas challenge. Our Strategy Our goal is to become a leading biopharmaceutical company focused on the development of therapeutics that modulate the immune system to prevent and treat conditions with significant unmet needs. The key components of our strategy are to: •Advance the development of Gemini for the prevention of acute kidney injury •Advance the development of Gemini for the treatment of chronic kidney disease 58 •Advance the development of Gemini for the prevention and treatment of post surgical infection •Advance the development of Gemini for the prevention of post burn infection Our Corporate History and Team The Company was incorporated in the state of Delaware on November 20, 2019 (originally as Petra Acquisition, Inc.) and is based in San Diego, California. We have assembled a management team of biopharmaceutical experts with extensive experience in drug development, manufacturing and commercialization of pharmaceutical products along with broad experience in building companies from inception, including La Jolla Pharmaceutical Company, Pluromed, Inc., and Horizon Pharma, Inc. We are also supported by a group of directors and leading investors whose collective experience will assist us in realizing our corporate strategy. BACKGROUND Acute Kidney Injury Overview AKI, also known as acute renal failure, is defined as a rapid loss of kidney function. AKI causes a build -upof waste products in blood and makes it more difficult for kidneys to maintain the correct balance of fluid in the body. AKI can also have a significant impact on other organs such as the brain, heart, and lungs. Due to its severe nature, AKI represents a significant and increasingly frequent health problem, especially in patients with co -morbiditiessuch as diabetes. Approximately 1%